$PVCT White Paper: Evidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials

The company, via Provectus News, circulated a white paper written by freelance medical writer Walter Alexander.

You can read the paper here, and I encourage you to do so if you already have not read it.

The paper and quotes reflect, in part, discussion about Moffitt and Provectus' work at AACR during a dinner attended by Alexander, Moffitt's Dr. Shari Pilon-Thomas, PhD, Melanoma Research Alliance's Wendy Selig, LiveSTRONG's Doug Ulman and Peter.

The white paper speaks to the overriding focus of oncology (e.g., FDA, Big Pharma, KOLs, clinicians, researchers, etc.), which is harnessing the immune system to treat and cure cancer, and the uniqueness of how PV-10 works in that regard.

I think the paper makes several tremendous points, and I will blog my thoughts in due course.